Cíl: Cílem naší průřezové studie bylo zjistit, jaké mají senioři znalosti o demenci a postoje k demenci a zda se tyto postoje a znalosti liší dle vybraných faktorů. Soubor a metodika: Výzkumný soubor tvořilo 269 účastníků Univerzity třetího věku v Ostravě, kteří byli starší 60 let. Pro sběr dat byla použita škála znalostí o demenci (Dementia Knowledge Scale) a škála postojů k lidem s demencí a k péči o ně (The Scale of Attitudes toward People with Dementia and their Care; APDC). Statistické vyhodnocení bylo provedeno pomocí Mann-Whitneyho testu a Spearmanova korelačního koeficientu. Výsledky: Senioři průměrně znali pět z osmi příznaků demence a pět z deseti rizikových faktorů. Lepší znalosti o příznacích demence měli senioři se zkušeností s péčí o osobu s demencí (p = 0,002) a ženy (p = 0,043). Více znalostí o rizikových faktorech demence uvedli muži (p = 0,028). Největší neznalost rizikových faktorů byla v oblasti obezity, vysokého krevního tlaku, diabetu a kouření. Mezi znalostmi a postoji vůči demenci nebyla zjištěna žádná souvislost. Závěr: Zvyšování znalostí seniorů o příznacích a rizikových faktorech demence může vést k vyššímu dodržování preventivních opatření a včasnému rozpoznání nemoci. Současně je vhodné do preventivních programů zařazovat intervence formující postoje seniorů k demenci a péči o osoby s demencí.
Aim: The aim of our cross-sectional study was to find out what knowledge seniors have about dementia and attitudes towards dementia and whether these attitudes and knowledge differ according to selected factors. Materials and methods: The research set consisted of 269 participants from the University of the Third Age in Ostrava who were over 60 years of age. The Dementia Knowledge Scale and The Scale of Attitudes toward People with Dementia and their Care (APDC) were used for data collection. Statistical evaluation was performed using the Mann-Whitney test and Spearman correlation coefficient. Results: On average, seniors knew five out of eight symptoms of dementia and five out of ten risk factors. Seniors with experience in caring for a person with dementia (P = 0.002) and women (P = 0.043) had better knowledge about the symptoms of dementia. Men reported greater knowledge about risk factors for dementia (P = 0.028). The greatest ignorance of risk factors was in the areas of obesity, high blood pressure, diabetes, and smoking. No association was found between knowledge and attitudes toward dementia. Conclusions: Increasing the knowledge of seniors about the symptoms and risk factors of dementia can lead to greater adherence to preventive measures and early recognition of the disease. At the same time, it is appropriate to include interventions shaping seniors‘ attitudes towards dementia and care for people with dementia in prevention programmes.
- MeSH
- Early Diagnosis MeSH
- Dementia * diagnosis prevention & control MeSH
- Humans MeSH
- Cross-Sectional Studies MeSH
- Surveys and Questionnaires MeSH
- Health Care Surveys methods MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Education methods MeSH
- Knowledge * MeSH
- Check Tag
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
B-cell non-Hodgkin lymphomas (B-NHL) represent the most common type of hematologic malignancies in the Western hemisphere. The therapy of all B-NHL is based on the combination of different genotoxic cytostatics and anti-CD20 monoclonal antibody (mAb) rituximab. Unfortunately, many patients relapse after the mentioned front-line treatment approaches. The therapy of patients with relapsed/refractory (R/R) B-NHL represents an unmet medical need. We designed, developed and tested novel actively targeted hybrid mAb-polymer-drug conjugate (APDC) containing anti-CD20, anti-CD38 or anti-CD19 mAbs. Biocompatible copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) with cytostatic agent doxorubicin attached via stimuli-sensitive hydrazone bond were employed for the mAb grafting. Anti-lymphoma efficacy of the APDC nanotherapeutics was evaluated in vivo on a panel of three patient-derived lymphoma xenografts derived from two patients with R/R B-NHL and one patient with so far untreated B-NHL. In both PDX models derived from patients with R/R B-NHL, the targeting with anti-CD38 antibody daratumumab demonstrated highly improved anti-lymphoma efficacy compared to the targeting with anti-CD20 rituximab, two experimental anti-CD19 antibodies and non-targeted controls. The results represent a proof-of-concept of a new algorithm of personalized anti-tumor therapy based on highly innovative APDC biomaterials.
- MeSH
- Pharmaceutical Preparations * MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Lymphoma, Non-Hodgkin * drug therapy MeSH
- Polymers therapeutic use MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Rituximab MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The widely-held assumption was that oxidative stress does not occur during seizures in the immature brain. The major finding of the present study concerns evidence of oxidative stress in the brain of immature rats during seizures induced by DL-homocysteic acid. Seizures were induced in 12-day-old rats by bilateral intracerebroventricular infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side) and oxidative stress was evaluated by in situ detection of superoxide anion (O(2)·(-)). Using hydroethidine (Het) method, the fluorescent signal of the oxidized products of Het (reflecting O(2)·(-) production) significantly increased (by 50%-60%) following 60 min lasting seizures in all the studied structures, namely CA1, CA3 and dentate gyrus of the hippocampus, cerebral cortex and thalamus. The enhanced O(2)·(-) production was substantially attenuated or completely prevented by substances providing an anticonvulsant effect, namely by a competitive NMDA receptor antagonist AP7, a highly selective and potent group II metabotropic glutamate receptor (mGluR) agonist 2R,4R-APDC and highly selective group III mGluR, subtype 8 agonist (S)-3,4-DCPG. Complete protection was achieved by two SOD mimetics Tempol and MnTMPYP which strongly suggest that the increased fluorescent signal reflects O(2)·(-) formation. In addition, both scavengers provided a partial protection against brain damage associated with the present model of seizures. Signs of neuronal degeneration, as evaluated by Fluoro-Jade B staining, were detected at 4h following the onset of seizures. The present findings thus suggest that the increased superoxide generation precedes neuronal degeneration and may thus play a causative role in neuronal injury. Occurrence of oxidative stress in brain of immature rats during seizures, as demonstrated in the present study, can have a clinical relevance for a novel approach to the treatment of epilepsy in children, suggesting that substances with antioxidant properties combined with the conventional therapies might provide a beneficial effect.
- MeSH
- 2-Amino-5-phosphonovalerate analogs & derivatives therapeutic use MeSH
- Anticonvulsants therapeutic use MeSH
- Time Factors MeSH
- Homocysteine analogs & derivatives toxicity MeSH
- Infusions, Intraventricular MeSH
- Rats MeSH
- Metalloporphyrins metabolism MeSH
- Disease Models, Animal MeSH
- Brain drug effects metabolism MeSH
- Statistics, Nonparametric MeSH
- Animals, Newborn MeSH
- Rats, Wistar MeSH
- Proline analogs & derivatives therapeutic use MeSH
- Superoxides metabolism MeSH
- Seizures chemically induced pathology prevention & control MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The present study has examined the anticonvulsant and neuroprotective effect of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), a selective agonist for group II metabotropic glutamate receptors (mGluRs) when given 10-15 min after the onset of seizures induced in 12-day-old rats by bilateral icv infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side). For biochemical analyses, rat pups were sacrificed during generalized clonic-tonic seizures, approximately 45-50 min after infusion of DL-HCA. Comparable time intervals were used for sacrificing the animals which received 2R,4R-APDC (0.05 nmol/side) or saline. The severity of seizures was influenced only slightly when the agonist was given after the onset of seizures, as evaluated both from the behavioral symptoms and from EEG recordings. A tendency to lower number and a shorter duration of seizures was outlined in animals posttreated with 2R,4R-APDC, but the differences did not reach the level of statistical significance. Cortical energy metabolite changes which normally accompany seizures in immature rats (large decrease of glucose and glycogen and a marked rise of lactate) were ameliorated only partially. The neuroprotective effect of 2R,4R-APDC was evaluated after 24 h and 6 days of survival following DL-HCA-induced seizures. Massive neuronal degeneration in many brain regions, mainly in the hippocampus and thalamus, following infusion of DL-HCA alone was only partially attenuated after 2R,4R-APDC posttreatment. The present findings clearly indicate that both anticonvulsant and neuroprotective effect of 2R,4R-APDC against DL-HCA-induced seizures is substantially diminished when the agonist is given after the onset of seizures as compared with its efficacy after the pretreatment (Exp. Neurol.192, 420-436, 2005).
- MeSH
- Excitatory Amino Acid Agonists therapeutic use MeSH
- Cytoprotection physiology drug effects MeSH
- Nerve Degeneration chemically induced physiopathology prevention & control MeSH
- Epilepsy drug therapy metabolism physiopathology MeSH
- Hippocampus metabolism growth & development drug effects MeSH
- Homocysteine analogs & derivatives pharmacology MeSH
- Convulsants pharmacology MeSH
- Rats MeSH
- Drug Interactions physiology MeSH
- Brain metabolism growth & development drug effects MeSH
- Neuroprotective Agents therapeutic use MeSH
- Rats, Wistar MeSH
- Proline analogs & derivatives therapeutic use MeSH
- Receptors, Metabotropic Glutamate agonists metabolism MeSH
- Drug Administration Schedule MeSH
- Aging metabolism MeSH
- Thalamus metabolism growth & development drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
